Press Releases July 16, 2026 08:00 AM

Integra LifeSciences to Host Second Quarter 2026 Financial Results Conference Call on July 29, 2026

Integra LifeSciences to report Q2 2026 earnings and host conference call on July 29, 2026

By Leila Farooq
Share
Twitter Reddit Facebook LinkedIn
IART

Integra LifeSciences Holdings Corporation announced it will release its second quarter 2026 financial results before market open on July 29, 2026. The company's management will hold a conference call and live webcast to discuss the results, emphasizing their role as a global medical technology leader specializing in neurosurgery and tissue reconstruction.

Integra LifeSciences to Host Second Quarter 2026 Financial Results Conference Call on July 29, 2026
IART
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Integra LifeSciences will release Q2 2026 earnings on July 29, 2026, prior to market open.
  • A conference call and live webcast will be held at 8:30 AM ET to discuss the results.
  • The company focuses on advanced medical technologies in neurosurgery and tissue reconstruction, impacting the healthcare sector.

PRINCETON, N.J., July 16, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release second quarter 2026 financial results on Wednesday, July 29, 2026, prior to the market open. In conjunction with the earnings release, Integra’s management team will host a conference call at 8:30 a.m. ET.

A live webcast will be available on the Investors section of the Company’s website at investor.integralife.com. For those planning to participate on the call, register here to receive dial-in details and an individual pin. While not required, joining 10 minutes before the event starts is recommended. A webcast replay of the conference call will be available on the Investors section of the Company’s website following the call. 

About Integra LifeSciences

Integra LifeSciences (Nasdaq: IART) is a global medical technology leader dedicated to restoring lives. We are advancing transformational care through impactful innovation in neurosurgery and tissue reconstruction, specialized fields that demand exceptional expertise and precision. Our portfolio of highly differentiated, gold-standard technologies are trusted by healthcare professionals to deliver life-saving care. For our latest news and information, visit www.integralife.com.

Investor Relations:
Chris Ward
(609) 772-7736
[email protected]   

Media Contact:
Laurene Isip
(609) 208-8121
[email protected]

Integra LifeSciences Holdings Corporation


Risks

  • Financial results may not meet investor expectations, potentially affecting stock price.
  • The medical technology sector is subject to regulatory and reimbursement challenges.
  • Market competition and operational risks could impact future performance.

More from Press Releases

Acoramidis Demonstrates Reversal of Cardiac Structural Disease Progression and Functional Decline and Significantly Increases Days Alive and Free from Hospitalization in ATTR-CM Aug 30, 2026 Cytokinetics Announces Additional Results from ACACIA-HCM and MAPLE-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology (ESC) Congress 2026 Aug 29, 2026 Tenax Therapeutics Announces Presentation of Phase 3 LEVEL Results in Late-Breaking Scientific Sessions at ESC Congress 2026 Aug 29, 2026 20/20 BioLabs Reschedules Investor Webinar to 2:00 p.m. Eastern Time on September 2, 2026 to Discuss OneTest™ Revenue and Expanding Commercial Opportunity Aug 28, 2026 Trinity Biotech Provides Diagnostics Business, Transformation And Corporate Update Aug 28, 2026